Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials
Overview of attention for article published in Lancet Oncology, January 2018
Altmetric Badge
About this Attention Score
-
In the top 5% of all research outputs scored by Altmetric
-
High Attention Score compared to outputs of the same age (95th percentile)
-
Good Attention Score compared to outputs of the same age and source (75th percentile)
Mentioned by
- news
- 3 news outlets
- 24 X users
- patent
- 2 patents
- f1000
- 1 research highlight platform
- guideline
- 1 clinical guideline source
Readers on
- mendeley
- 373 Mendeley